When: $245-250 / bear downside target

Then: Re-enter on deeper pullback

When: Below $240 only on confirmed fundamental catalyst

Then: Re-enter only with specific positive catalyst

HOLD - Full position, no trim

• Current price at $266 with 10 EMA at $260.62; all three moving averages stacked in bullish order
• Forward P/E of 16.2x is not expensive given $16.87B in free cash flow, 40% operating margins, and 72.8% gross margins
• Q2 2026 revenue grew 10.2% year over year, the highest quarter in the dataset; operating margin recovered to 39.6%
• Low beta of 0.281 means ABBV declines less than the market in downturns and captures relative outperformance when it matters most
• 2.62% dividend yield is more attractive, not less, in a macro environment where 10-year yields are at 5%
• MACD line is above signal with positive histogram, 50 SMA acted as foothold during August dip
• TTM P/E of 74 is distorted by one-time impairment charges; does not reflect normalized earnings power
• Dividend held at $1.73 all year with track record of dividend growth
• Capital rotating out of high-flyers in sector would flow into more defensive name with better yield, which is ABBV
• Transaction costs, tax events, and opportunity cost of dry powder make trimming at best a wash and likely underperformance

→ vs aggressive: The $245 price target is unsupported and was 'pulled out of the air' as a support level based on technical structure; no catalyst identified for ABBV to fall from $266 to $245

→ vs aggressive: CITATION of 70% SKYRIZI/RINVOQ concentration as 'binary risk' is intellectually dishonest; if SKYRIZI prints 18% instead of 22% growth, stock doesn't open at $245 next morning—it chops for a month before recovering or not

→ vs aggressive: Calling Citadel adding to position a 'lagging indicator' is a half-truth; sophisticated capital with patient mandates sees value here and we don't know they're trimming

→ vs aggressive: Technical case overreaches—'$263-267 distribution and textbook exhaustion' ignores that price held above 10 EMA at $260.62, MACD is bullish, 50 SMA acted as foothold; this is an intact uptrend with a pullback that already happened, not exhaustion

→ vs aggressive: Transaction costs, tax events, and opportunity cost of dry powder; if ABBV doesn't pull back to $245-$255 for a year and sits at $270-280, trimming guarantees underperformance

→ vs neutral: Wait-for-$245 mentality is dangerous—investors who waited for pullbacks that never came in defensive compounders have spent three years watching them grind from $130 to $260 while collecting dividends

REDUCE EXPOSURE via 25-40% tactical trim with 3-4 tranche execution at resistance ($266-267), tight stop at $271 (1.4 ATR), and re-entry tiers at $255/$245; maintain core 60-75% position; trim size should be tiered based on price action (15-20% if resistance breaks, up to 40% if resistance holds and rolls over); add explicit SKYRIZI monitoring trigger below 18% YoY growth

• Relative valuation concern valid: 16.2x forward vs JNJ at 15x and PFE at 12x for concentrated growth name
• SKYRIZI/RINVOQ concentration is the dominant risk but doesn't justify full exit
• Macro backdrop (5% yields, zero cuts priced) creates tail risk for defensive bid
• Aggressive analyst's 'distribution' call overreached: technical report explicitly called it 'quiet-accumulation signature,' not distribution
• Fabricated statistic: '70% symmetric setup resolution' has no empirical basis in equity markets
• Citadel cost-basis speculation unsupported: visible data shows accumulation, not trimming
• PEG of 0.54 not 'fantasy': consensus estimates are best available forecasting mechanism with no ABBV-specific bias evident
• Conservative analyst's shelter/insurance analogy weak: ABBV is an equity position, not a hedge; it has appreciated substantially ($190 to $264 in 5 months) and now carries real downside at double-top resistance
• Backward-looking 'waiting for pullbacks that never came' argument irrelevant: $130 to $260 journey is trailing context, not forward outlook
• Three conservative triggers ($250 close, SKYRIZI miss, macro deterioration) are too late: they arrive after 5-10% drawdowns rather than preempting them
• Tax/transaction cost argument overweighted: 25-40% trim spread across 3-4 tranches minimizes friction; friction is single-digit percentage on trimmed portion only
• Dry powder paired with explicit re-entry tiers ($255, $245) creates structured improvement to risk profile, not 'wash at best'
• Bottom line: fundamental quality and defensive characteristics intact but don't justify full hold at resistance zone with concentration risk present
• Refinement 1: Tier trim size - shrink to 15-20% if ABBV breaks and closes above $267 on volume expansion (resistance thesis invalidated); extend toward 40% if fails at resistance and rolls over (bear case confirming)
• Refinement 2: Add explicit SKYRIZI monitoring trigger - if Q3 prints SKYRIZI growth below 18% YoY or guides to deceleration, accelerate trim regardless of price

→ vs aggressive: Distribution call at $263-267 contradicted by technical report's own characterization of 'quiet-accumulation signature'; accumulation reading equally valid and should not be discarded

→ vs aggressive: Claim that 'symmetric setups resolve directionally ~70% of the time within 5-10 sessions' is fabricated with no empirical basis in equity markets

→ vs aggressive: Citadel cost-basis speculation unsupported: cannot override documented institutional accumulation with unverified entry price assumptions

→ vs aggressive: PEG of 0.54 not 'fantasy' - consensus estimates are best available forecasts with no ABBV-specific systematic bias evident

→ vs conservative: Shelter/insurance analogy analytically weak: ABBV is an equity position with low beta, not a free hedge; has appreciated substantially ($190 to $264) and now carries downside at resistance

→ vs conservative: Backward-looking 'pullbacks that never came' argument irrelevant: trailing context ($130 to $260) doesn't dictate forward outlook from $264

→ vs conservative: Three triggers too late - $250 close = 5% drawdown, SKYRIZI miss = 7-10% move; waiting for confirmation means trimming into weakness rather than strength

→ vs conservative: Tax/transaction cost argument overweighted: friction is single-digit percentage on trimmed portion only; dry powder at money market rates is not missed opportunity when paired with re-entry tiers